Published Paper Details:

The CRISPR/ Cas9 technology which can correct genes, control transcription, model diseases, and visualize nucleic acids. Nevertheless, this is not an easy task because it has a low transfection efficiency rate as well as the off target risk associated with it. The extensive report on the CRISPR/CaSN system is delivered outlining viral as well as non-viral vehicles. The technological landscape of applied delivery technologies in CRISPR/Cas9-inspired clinical trials is clearly presented via a thorough examination. The spotlight is directed towards rational designs for non-viral vectors tasked with delivering the three pivotal forms of the CRISPR/Cas9 system: These include plasmid DNA, mRNA, and RNP, Cas9 protein complexed with guide RNA. The complexities associated with vector-derived methods of alleviating the off target worries are comprehensively scrutinized. Surprisingly, it focuses on the underlying mechanisms, uses, and obstacles concerning using CRISPR/Cas9 system for genome editing. Specific inherent in the system-guided Cas9 for cutting, resulting in insertions, deletions or substitution are emphasised. Besides, CRISPR/Cas9 clinical therapeutic potential is considered in relation to recent findings utilizing the genetic tools of bacterial adaptive immunity for site-specific cleavage and mutagenesis. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), and Cas proteins have changed genetics studies worldwide, transforming gene therapy landscapes. The conventional gene transfer with viral vector-mediated delivery is problematic due to the risk of insertional oncogenesis and immune-mediated toxicity whereas CRISPR makes it highly attractive substitution. Finally, recent gene therapy trials are considered and the ways through which one is able to navigate the intricacies of this revolutionary, yet nascent practice are contemplated. Addressing the limits of CRISPR/Cas9, as illustrated by its impact on moving gene therapy paradigms forward should point towards safe and efficient clinical translation.